1. Home
  2. NRIX vs IMKTA Comparison

NRIX vs IMKTA Comparison

Compare NRIX & IMKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • IMKTA
  • Stock Information
  • Founded
  • NRIX 2009
  • IMKTA 1963
  • Country
  • NRIX United States
  • IMKTA United States
  • Employees
  • NRIX N/A
  • IMKTA N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • IMKTA Food Chains
  • Sector
  • NRIX Health Care
  • IMKTA Consumer Staples
  • Exchange
  • NRIX Nasdaq
  • IMKTA Nasdaq
  • Market Cap
  • NRIX 1.1B
  • IMKTA 1.2B
  • IPO Year
  • NRIX 2020
  • IMKTA N/A
  • Fundamental
  • Price
  • NRIX $9.50
  • IMKTA $61.49
  • Analyst Decision
  • NRIX Strong Buy
  • IMKTA
  • Analyst Count
  • NRIX 17
  • IMKTA 0
  • Target Price
  • NRIX $30.71
  • IMKTA N/A
  • AVG Volume (30 Days)
  • NRIX 942.9K
  • IMKTA 124.4K
  • Earning Date
  • NRIX 04-08-2025
  • IMKTA 05-08-2025
  • Dividend Yield
  • NRIX N/A
  • IMKTA 1.07%
  • EPS Growth
  • NRIX N/A
  • IMKTA N/A
  • EPS
  • NRIX N/A
  • IMKTA 3.26
  • Revenue
  • NRIX $56,417,000.00
  • IMKTA $5,410,455,434.00
  • Revenue This Year
  • NRIX $15.73
  • IMKTA N/A
  • Revenue Next Year
  • NRIX N/A
  • IMKTA N/A
  • P/E Ratio
  • NRIX N/A
  • IMKTA $18.73
  • Revenue Growth
  • NRIX N/A
  • IMKTA N/A
  • 52 Week Low
  • NRIX $8.18
  • IMKTA $58.92
  • 52 Week High
  • NRIX $29.56
  • IMKTA $82.01
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 35.33
  • IMKTA 45.47
  • Support Level
  • NRIX $9.02
  • IMKTA $59.41
  • Resistance Level
  • NRIX $11.56
  • IMKTA $63.74
  • Average True Range (ATR)
  • NRIX 0.61
  • IMKTA 1.63
  • MACD
  • NRIX -0.07
  • IMKTA -0.11
  • Stochastic Oscillator
  • NRIX 14.29
  • IMKTA 33.49

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About IMKTA Ingles Markets Incorporated

Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.

Share on Social Networks: